Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7349
Source ID: NCT01982253
Associated Drug: Fasiglifam
Title: Fasiglifam 25 mg BID vs 50 mg QD
Acronym:
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT01982253/results
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Fasiglifam|DRUG: Placebo to fasiglifam
Outcome Measures: Primary: Change From Baseline in HbA1c at Week 12., The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline., Baseline and Week 12 | Secondary: Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12, The change between the FPG value collected at week 12 or final visit relative to baseline., Baseline and Week 12
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 10
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2013-10
Completion Date: 2014-01
Results First Posted: 2016-10-07
Last Update Posted: 2016-10-07
Locations: Goodyear, Arizona, United States|Long Beach, California, United States|Los Angeles, California, United States|North Hollywood, California, United States|Norwalk, California, United States|Tustin, California, United States|Boynton Beach, Florida, United States|Coral Gables, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Franklin, Indiana, United States|Greenfield, Indiana, United States|Muncie, Indiana, United States|Council Bluffs, Iowa, United States|Topeka, Kansas, United States|Lexington, Kentucky, United States|Metairie, Louisiana, United States|Flint, Michigan, United States|Albuquerque, New Mexico, United States|Charlotte, North Carolina, United States|Greensboro, North Carolina, United States|Mooresville, North Carolina, United States|Morganton, North Carolina, United States|Salisbury, North Carolina, United States|Maumee, Ohio, United States|Norman, Oklahoma, United States|Corvallis, Oregon, United States|Portland, Oregon, United States|Harleysville, Pennsylvania, United States|Levittown, Pennsylvania, United States|Uniontown, Pennsylvania, United States|Greer, South Carolina, United States|Carrollton, Texas, United States|Dallas, Texas, United States|Edinburg, Texas, United States|Houstan, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Spring, Texas, United States|Salt Lake City, Utah, United States|Burke, Virginia, United States|Manassas, Virginia, United States|Byala, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Ruse, Bulgaria|Sevlievo, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Lodz, Poland|Oswiecim, Poland|Poznan, Poland|Rzeszow, Poland|Sobotka, Poland|Torun, Poland|Zgierz, Poland|Baia Mare, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Iasi, Romania|Oradea, Romania|Ploiesti, Romania|Bardejov, Slovakia|Bratislava, Slovakia|Dolny Kubin, Slovakia|Komarno, Slovakia|Levice, Slovakia|Lucenec, Slovakia|Nitra, Slovakia|Pezinok, Slovakia|Sabinov, Slovakia|Stropkov, Slovakia|Sturovo, Slovakia|Svidnik, Slovakia|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Kharkiv, Ukraine|Kyiv, Ukraine|Simferopol, Ukraine|Ternopil, Ukraine|Vinnytsia, Ukraine
URL: https://clinicaltrials.gov/show/NCT01982253

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress